Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2016, Article ID 2382031, 3 pages
http://dx.doi.org/10.1155/2016/2382031
Case Report

Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature

Hadassah University Hospital Mount Scopus, Jerusalem, Israel

Received 14 June 2016; Revised 17 August 2016; Accepted 22 August 2016

Academic Editor: Erich Cosmi

Copyright © 2016 Tal Saar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. T. Bateman, K. M. Shaw, E. V. Kuklina, W. M. Callaghan, E. W. Seely, and S. Hernández-Díaz, “Hypertension in women of reproductive age in the United States: NHANES 1999–2008,” PLoS ONE, vol. 7, no. 4, Article ID e36171, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. W. O. Cooper, S. Hernandez-Diaz, P. G. Arbogast et al., “Major congenital malformations after first-trimester exposure to ACE inhibitors,” The New England Journal of Medicine, vol. 354, no. 23, pp. 2443–2451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. R. Caton, E. M. Bell, C. M. Druschel et al., “Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations,” Hypertension, vol. 54, no. 1, pp. 63–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Lennestål, P. O. Olausson, and B. Källén, “Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notablythe presence of congenital heart defects in the infants,” European Journal of Clinical Pharmacology, vol. 65, no. 6, pp. 615–625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D.-K. Li, C. Yang, S. Andrade, V. Tavares, and J. R. Ferber, “Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study,” British Medical Journal, vol. 343, no. 7829, Article ID d5931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Bullo, S. Tschumi, B. S. Bucher, M. G. Bianchetti, and G. D. Simonetti, “Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review,” Hypertension, vol. 60, no. 2, pp. 444–450, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Tabacova, R. Little, Y. Tsong, A. Vega, and C. A. Kimmel, “Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment,” Pharmacoepidemiology and Drug Safety, vol. 12, no. 8, pp. 633–646, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Shotan, J. Widerhorn, A. Hurst, and U. Elkayam, “Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use,” The American Journal of Medicine, vol. 96, no. 5, pp. 451–456, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Celentano, F. Prefumo, E. di Vera, A. Iannicco, D. P. Gallo, and M. Liberati, “Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker,” Pediatric Nephrology, vol. 23, no. 2, pp. 333–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Chisholm, N. C. Chescheir, and M. Kennedy, “Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure,” American Journal of Perinatology, vol. 14, no. 9, pp. 511–513, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Berkane, P. Carlier, L. Verstraete, E. Mathieu, N. Heim, and S. Uzan, “Fetal toxicity of valsartan and possible reversible adverse side effects,” Birth Defects Research Part A—Clinical and Molecular Teratology, vol. 70, no. 8, pp. 547–549, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. F. H. Steffensen, G. L. Nielsen, H. T. Sorensen, C. Olesen, and J. Olsen, “Pregnancy outcome with ACE-inhibitor use in early pregnancy,” The Lancet, vol. 351, article 596, 1998. View at Google Scholar · View at Scopus
  13. R. A. Martin, K. L. Jones, A. Mendoza, M. Barr Jr., and K. Benirschke, “Effect of ACE inhibition on the fetal kidney: decreased renal blood flow,” Teratology, vol. 46, no. 4, pp. 317–321, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. M.-A. Lambot, D. Vermeylen, J.-C. Noël et al., “Angiotensin-II-receptor inhibitors in pregnancy,” The Lancet, vol. 357, no. 9268, pp. 1619–1620, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. R. M. Cox, J. M. Anderson, and P. Cox, “Defective embryogenesis with angiotensin II receptor antagonists in pregnancy,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 110, no. 11, pp. 1038–1040, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. M. Laudy and J. W. Wladimiroff, “The fetal lung 2: pulmonary hypoplasia,” Ultrasound in Obstetrics and Gynecology, vol. 16, no. 5, pp. 482–494, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Alwan, J. E. Polifka, and J. M. Friedman, “Angiotensin II receptor antagonist treatment during pregnancy,” Birth Defects Research Part A—Clinical and Molecular Teratology, vol. 73, no. 2, pp. 123–130, 2005. View at Publisher · View at Google Scholar · View at Scopus